Zankiren | CAS# 138742-43-5 | Renin Inhibitor

MedKoo Cat#: 571190 | Name: Zankiren

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zankiren is a renin inhibitor. It can reduce blood pressure, plasma renin activity, and angiotension II. It can decrease blood pressure and circulating components of the RAS in normotensive volunteers as a result of documented absorption.

Chemical Structure

Zankiren

CAS#138742-43-5

Theoretical Analysis

MedKoo Cat#: 571190

Name: Zankiren

CAS#: 138742-43-5

Chemical Formula: C35H55N5O6S2

Exact Mass: 705.3594

Molecular Weight: 705.97

Elemental Analysis: C, 59.55; H, 7.85; N, 9.92; O, 13.60; S, 9.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Zankiren; A 72617; A-72517; A72517

IUPAC/Chemical Name

4-Thiazolepropanamide, N-((1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-(((2S)-2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (alphaS)-

InChi Key

YFDSDRDMDDGDFC-HOQQKOLYSA-N

InChi Code

InChI=1S/C35H55N5O6S2/c1-25(2)18-32(41)33(42)30(20-27-12-8-5-9-13-27)37-35(44)31(21-29-22-47-24-36-29)38-34(43)28(19-26-10-6-4-7-11-26)23-48(45,46)40-16-14-39(3)15-17-40/h4,6-7,10-11,22,24-25,27-28,30-33,41-42H,5,8-9,12-21,23H2,1-3H3,(H,37,44)(H,38,43)/t28-,30+,31+,32+,33-/m1/s1

SMILES Code

O=C(N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)CC(C)C)[C@@H](NC([C@@H](CS(=O)(N2CCN(C)CC2)=O)CC3=CC=CC=C3)=O)CC4=CSC=N4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 705.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ménard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation. 1995 Jan 15;91(2):330-8. PubMed PMID: 7805235. 2: Jadhav M, Yeola C, Zope G, Nabar A. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. J Postgrad Med. 2012 Jan-Mar;58(1):32-8. doi: 10.4103/0022-3859.93250. Review. PubMed PMID: 22387646. 3: Tzoupis H, Leonis G, Avramopoulos A, Reis H, Czyżnikowska Ż, Zerva S, Vergadou N, Peristeras LD, Papavasileiou KD, Alexis MN, Mavromoustakos T, Papadopoulos MG. Elucidation of the binding mechanism of renin using a wide array of computational techniques and biological assays. J Mol Graph Model. 2015 Nov;62:138-49. doi: 10.1016/j.jmgm.2015.09.015. Epub 2015 Sep 25. PubMed PMID: 26421414. 4: Fisher ND, Hollenberg N. Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther. 1995 Mar;57(3):342-8. PubMed PMID: 7697952. 5: Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005 Feb;23(2):417-26. PubMed PMID: 15662231. 6: Rosenberg SH, Spina KP, Condon SL, Polakowski J, Yao Z, Kovar P, Stein HH, Cohen J, Barlow JL, Klinghofer V, et al. Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517). J Med Chem. 1993 Feb 19;36(4):460-7. PubMed PMID: 8474102. 7: Gupta SL, Patel JP, Jones DL, Partipilo RW. Parenteral formulation development of renin inhibitor Abbott-72517. J Pharm Sci Technol. 1994 Mar-Apr;48(2):86-91. PubMed PMID: 8032800. 8: Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005 Mar;16(3):592-9. Epub 2005 Feb 9. Review. PubMed PMID: 15703270. 9: Kleinert HD, Rosenberg SH, Baker WR, Stein HH, Klinghofer V, Barlow J, Spina K, Polakowski J, Kovar P, Cohen J, et al. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science. 1992 Sep 25;257(5078):1940-3. PubMed PMID: 1411510. 10: Frishman WH, Fozailoff A, Lin C, Dike C. Renin inhibition: a new approach to cardiovascular therapy. J Clin Pharmacol. 1994 Sep;34(9):873-80. Review. PubMed PMID: 7983230. 11: Sepehrdad R, Frishman WH, Stier CT Jr, Sica DA. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Cardiol Rev. 2007 Sep-Oct;15(5):242-56. Review. PubMed PMID: 17700383. 12: Panzenbeck MJ, Loughnan CL, Madwed JB, Winquist RJ, Fogal SE. Captopril-induced hypotension is inhibited by the bradykinin blocker HOE-140 in Na(+)-depleted marmosets. Am J Physiol. 1995 Oct;269(4 Pt 2):H1221-8. PubMed PMID: 7485552. 13: Wessale JL, Kleinert HD, Calzadilla SV, Kovar PJ, Rosenberg SH. Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs. Am J Hypertens. 1993 Jun;6(6 Pt 1):514-21. PubMed PMID: 8343235.